TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18971537
Drug: Calcium Channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel Blocker (CCB)
Study: 24360178
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II Receptor Antagonist (ARB)
Study: 21900784
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg daily)
Study: 3350281
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily)
Study: 19912686
Drug: Lamivudine (LMV)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (LMV) 100 mg per day
Study: 6861770
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg b.i.d.
Study: 28802777
Drug: LIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA with liposomal bupivacaine (LB) 266 mg/20 mL (admixed with bupivacaine HCl 0.5%, 20 mL)
Study: 28802777
Drug: LIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA with bupivacaine HCl 0.5%, 20 mL
Study: 8864793
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g, 150 ml, 15 min)
Study: 8864793
Drug: Placebo (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (150 ml NaCl)
Study: 8864793
Drug: L-arginine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (in PPH patients)
Study: 27012596
Drug: Rivastigmine Patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine Patch (9.5 mg/24 h)
Study: 27012596
Drug: Rivastigmine Capsule
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine Capsule (6 mg Twice Daily)
Study: 25423958
Drug: Bleeper Sv
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bleeper Sv radiation monitor (real-time operator dose reporting through auditory feedback)
Study: 3825935
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg slow-release IS-5MN
Study: 28857848
Drug: IV amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV amikacin 20 mg/kg once daily
Study: 28857848
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin 400 mg twice daily
Study: 25880761
Drug: Fresh frozen
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh frozen plasma (FFP) transfusion (12 ml/kg)
Study: 19100647
Drug: Irinotecan (I)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (I) monotherapy (300mg/m² i.v. on day 1) every 3 weeks
Study: 19100647
Drug: Irinotecan (I)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (I) monotherapy
Study: 11765070
Drug: Opioids (morphine)
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (morphine)
Study: 11765070
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (TC)
Study: 8024947
Drug: Single enantiomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single enantiomer formulation (SEF) of (S)-atenolol, 50 mg
Study: 8024947
Drug: Racemic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic mixture (Tenormin, TMN) of (R,S)-atenolol, 100 mg
Study: 8024947
Drug: Single enantiomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single enantiomer formulation (SEF) of (S)-atenolol
Study: 7082501
Drug: Nitroprusside infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside infusion
Study: 5823051
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives with low dose progestogen and high dose oestrogen
Study: 5823051
Drug: Sequential oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential oral contraceptives
Study: 5823051
Drug: Progestogenic combined
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogenic combined preparations
Study: 5823051
Drug: Oestrogenic sequential
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogenic sequential regimens and low-dose progestogen-only regimens
Study: 26385346
Drug: Intranasal S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal S. salivarius 24SMB
Study: 24217026
Drug: Capsule A
Normalized name: capsule administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule A containing artificial food colorings (AFCs)
Study: 24217026
Drug: Capsule B
Normalized name: Emend 80mg Capsule BiPack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule B containing sodium benzoate
Study: 11016670
Drug: Neomycin sulfate
Normalized name: Neomycin Sulfate
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin sulfate patch tests with various doses and vehicles
Study: 11016670
Drug: Serial-dose series
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial-dose series for time intervals ranging from 3 to 96 h
Study: 8104509
Drug: Debrisoquin (peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debrisoquin (peripheral monoamine oxidase inhibitor)
Study: 2425168
Drug: Hydralazine (0.05-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (0.05-0.3 mg/kg, bolus injections)
Study: 29561783
Drug: MK7 (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK7 (360 mcg/day)
Study: 26611780
Drug: Lactobacillus salivarius
Normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus salivarius PS2 (9 log10 colony‐forming units daily from week 30 of pregnancy until delivery)
Study: 24533064
Drug: H7N3 live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H7N3 live attenuated influenza vaccine
Study: 1837510
Drug: Half-sized lunch
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-sized lunch with reduced insulin dose
Study: 7028238
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no-drug conditions
Study: 20568955
Drug: Combined metformin-clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metformin-clomiphene citrate (CC)
Study: 8986681
Drug: Iron pill
Normalized name: Elmiron Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron pill (placebo, n = 14)
Study: 20506062
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream formulation of Ruxolitinib
Study: 18397484
Drug: 8-week pegIFN-alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week pegIFN-alpha-2a therapy
Study: 18397484
Drug: 24-week pegIFN-alpha-2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week pegIFN-alpha-2a therapy
Study: 6180901
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of triprolidine and pseudoephedrine
Study: 30823945
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (Control)
Study: 25302456
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 1% lignocaine PPNB and placebo suppository
Study: 14990632
Drug: Gefitinib 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 500 mg/d
Study: 15838439
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching with near activities
Study: 15838439
Drug: 2 hours
Normalized name: PATCH, TRANSDERMAL 72 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hours of daily patching without near activities
Study: 12904966
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg)
Study: 25702958
Drug: High dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dairy protein (HP-D, >1.2 g of protein/kg body weight/d; ∼27 g/d dairy protein)
Study: 23688276
Drug: MPI Cephalexin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPI Cephalexin® tablet
Study: 22736448
Drug: 38% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride (SDF) solution, annual application
Study: 11428472
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg at bedtime, increased to 20 mg if necessary) with behavioral modification
Study: 11428472
Drug: Behavioral modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral modification alone (calorie control and daily walking for 30 minutes)
Study: 9876998
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral administration of alpha-lipoic acid
Study: 9876998
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral administration of alpha-lipoic acid
Study: 9876998
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous administration of alpha-lipoic acid
Study: 2786856
Drug: Erdosteine 900
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 900 mg/day for one month
Study: 31928551
Drug: Peer‐identified change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer‐identified change agents (PICAs)
Study: 31928551
Drug: Management‐selected change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management‐selected change agents (MSCAs)
Study: 26062124
Drug: Tumor-primed NK
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-primed NK cells (TpNK) infusion
Study: 7851099
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment Teams (CTTs)
Study: 29703031
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy administered in the region of the parotid glands bilaterally and in the regions of the submandibular and sublingual glands
Study: 25424454
Drug: 2 h
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h 75 g OGTT using the IADPSG criteria
Study: 21593803
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) 600 mg intravenously once daily for 2 weeks
Study: 12505224
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus simvastatin (pooled doses)
Study: 12505224
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus simvastatin 10 mg
Study: 12505224
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg alone
Study: 11760
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high dose fluphenazine decanoate (250 mg weekly)
Study: 21478660
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (closed treatment)
Study: 18342398
Drug: High-dose Phe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Phe (10 g)
Study: 18342398
Drug: Low-dose Phe
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Phe (5 g Phe and 5 g glucose)
Study: 18342398
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 g glucose)
Study: 10826458
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg once daily
Study: 11115698
Drug: DNA vaccine
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA vaccine (1, 2, or 4 microg)
Study: 30693609
Drug: Magnesium (250
Normalized name: magnesium gluconate 12.5 mg magnesium (250 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (250 mg) plus Vitamin E (400 IU)
Study: 12367545
Drug: Swanson silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swanson silicone trapezium implant
Study: 1661121
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) given as a single predialysis bolus injection
Study: 6807125
Drug: Doxapram (1‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (1‐1.5 mg/kg)
Study: 28656922
Drug: Casein phosphopeptide‐amorphous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein phosphopeptide‐amorphous calcium fluoride phosphate (CPP‐ACFP) applied daily for 4 min for 4 weeks
Study: 25125441
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation combined with repetitive task practice therapy
Study: 11895217
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg orally 4x/day for 3 days)
Study: 10090447
Drug: Dorzolamide three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide three times daily for the first ten days and latanoprost once daily for the second ten days (Group 2)
Study: 25216510
Drug: LX4211 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX4211 75 mg once daily
Study: 25216510
Drug: LX4211 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX4211 200 mg once daily
Study: 25216510
Drug: LX4211 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX4211 200 mg twice daily
Study: 25216510
Drug: LX4211 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX4211 400 mg once daily
Study: 9298509
Drug: Nicotine (0.003-0.012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.003-0.012 mg/kg)
Study: 9298509
Drug: Atropine (0.001-0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.001-0.01 mg/kg)
Study: 19176272
Drug: Goserelin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin and flutamide (STAD) for 3 or 6 months before and during radiation therapy (66 Gy to the prostate and seminal vesicles)
Study: 19176272
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (XRT) alone
Study: 15500814
Drug: Cognitive preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive preparation for video feedback
Study: 2225508
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics continued for at least 48 hours in patients requiring a tracheotomy
Study: 25988676
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) long-acting formulation, 300 mg
Study: 25988676
Drug: Rilpivirine (RPV)
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (RPV) long-acting formulation, 600 mg
Study: 22067758
Drug: Doxycycline (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (40 mg daily)
Study: 11683740
Drug: Somatostatin-14 (S-14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin-14 (S-14) infusion for 7 days
Study: 9893697
Drug: Hormonotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonotherapy and chemotherapy
Study: 9893697
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (letrozole, anastrozole)
Study: 2303582
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg tablets
Study: 2303582
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin tablets
Study: 2303582
Drug: ibuprofen suspensions
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen suspensions
Study: 2303582
Drug: ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen tablets
Study: 366897
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug treatment (vincristin, 5‐fluoruracil, methotrexate, cyclophosphane, prednisolone)
Study: 366897
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug treatment plus ovariectomy and continuous administration of prednisolone, testosterone‐propionate or synoestrol
Study: 25356603
Drug: Nilotinib 300
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg bid
Study: 25356603
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg qd
Study: 23769755
Drug: 4L polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4L polyethylene glycol solution
Study: 18637100
Drug: Topical estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estriol
Study: 17924131
Drug: 0.15 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/m3 epsilon-caprolactam vapours
Study: 17924131
Drug: 0 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/m3 epsilon-caprolactam vapours (control)
Study: 9876789
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA with pethidine
Study: 26886884
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) for urinary incontinence, 12 weekly sessions
Study: 23094941
Drug: RealFX™ Q‐Plus™
Approvals — FDA: no, EMA: no, PMDA: no
Description: RealFX™ Q‐Plus™ Chews (500 mg quercetin)
Study: 23094941
Drug: First Strike™
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Strike™ Bars (500 mg quercetin)
Study: 23094941
Drug: Tang(®) suspension
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tang(®) suspension (500 mg quercetin)
Study: 12485286
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% and timolol 0.5% fixed combination twice daily
Study: 25766269
Drug: CaCBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCBT plus Treatment As Usual (TAU)
Study: 15126574
Drug: Pyridostigmine (PD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD, 120 mg per os)
Study: 15126574
Drug: Pirenzepine (PZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PZ, 100 mg per os)
Study: 28407162
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac preoperatively
Study: 18568885
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac
Study: 26204202
Drug: Doses greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses greater than 300 Gy
Study: 8314468
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (5 million units, three times weekly)
Study: 22074724
Drug: Intravenous glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glulisine insulin using a paper-based glucose-lowering algorithm followed by once-daily subcutaneous insulin glargine for 30 days
Study: 11331318
Drug: Intensive combination
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive combination chemotherapy without local radiation therapy
Study: 36250
Drug: Indoramin (76
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (76 mg/day)
Study: 36250
Drug: Prazosin (8.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (8.2 mg/day)
Study: 36250
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpha‐adrenoreceptor blockers with beta‐adrenoreceptor blockade
Study: 25445632
Drug: L-arginine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine + nitrate (6 g L-arginine and 614 mg nitrate)
Study: 25445632
Drug: Nitrate alone
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate alone (614 mg nitrate)
Study: 25445632
Drug: L-arginine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine + nitrate and nitrate alone
Study: 12910485
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplements
Study: 24763358
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for 8 weeks
Study: 24660604
Drug: Reduning injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduning injection and Western Medicine (Group C)
Study: 24660604
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine (Group A)
Study: 19691852
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of intravenous-grade 70% ethanol into each lumen of the catheter once a week
Study: 2543656
Drug: Combined progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined progestin and estrogen (medroxyprogesterone acetate, 20 mg tid, and Premarin, 1.25 mg bid)
Study: 26444863
Drug: Online monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Online monthly assessment + DEAL + 12-month access to a social networking site (Breathing Space)
Study: 26444863
Drug: Online monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Online monthly self-assessments